SlideShare una empresa de Scribd logo
1 de 18
Descargar para leer sin conexión
Jefferies Healthcare
         Conference




           June 26, 2007
Safe Harbor Disclaimer
                                                                                 »



»
The statements in this presentation which are not historical
facts or information are forward-looking statements. These
forward-looking statements involve risks and uncertainties that
could cause the outcome to be materially different. Certain of
these risks and uncertainties are described in the Quest
Diagnostics Incorporated SEC filings, including our latest Form
10-K. Additional risks may arise from unanticipated events.


A copy of this presentation is available on
our website at www.questdiagnostics.com

                                                            Patients Growth People
Who is Quest Diagnostics?
                                                                      »



»Leader in Providing Healthcare Insights and Solutions
  Comprehensive Diagnostic Testing
      Routine ——» Esoteric
        • Diagnose
        • Monitor
        • Predict
        • Prevent
   Advanced Information Technology Solutions
      Improve Care and Efficiency
   Facilitate Introduction of New Therapeutics
      Clinical Trials Testing

  Touching the Lives of Patients >150 Million Times in 2006
                                                 Patients Growth People
Quest Diagnostics: The Leader
                                                                                              »



» DiagnosticBTesting
US
Market: ~$45




  Source: Washington G-2 Reports and company estimates
          Quest Diagnostics data is proforma for AmeriPath acquisition
                                                                         Patients Growth People
A Leader Across All Product Lines
                                                                                                       »



»




                                                                       $ in millions
    Based on 2006 Actual Results, proforma for AmeriPath acquisition

                                                                                  Patients Growth People
Favorable Industry Trends
                                                                         »



»   Essential Healthcare Service
                      Growing and Aging Population
                      Innovations in Science & Medicine
                      Personal Interest in Health
                      Convergence of Technologies
                       • Genetic Predisposition
                       • Diagnostic Testing
                       • Diagnostic Imaging
                       • Information Technology
    Influences >70% of Healthcare Decisions
                                                    Patients Growth People
Why Quest Diagnostics?
                                                                   »



»   Unique Value Proposition

       Superior Patient Experience

       Six Sigma Quality

       Unparalleled Access and Distribution

       Innovative Science & Medicine

       Advanced Information Technology

    Sustainable Advantage
                                              Patients Growth People
Patient Service Centers
                                       and Laboratory Network
                                                                                    »



    »




    PSCs
    IOPs
    RRLs
∃   Main Labs
∃
~2,300 Laboratories and Patient Service Centers Serving Half of US Physicians
                                                               Patients Growth People
Electronic Connectivity:
                                        Care360 Network
                                                                           »



 »




>100,000 Physician Users and Growing by >1,000 Physicians Each Month
                                                      Patients Growth People
Preferred by Physicians
                                                 »



»   Recent Nationwide Survey
    Completed by National
    Analysts Worldwide


    Asked If Physicians Had a Preference
    Between 2 Largest Labs:


      Majority Had a Preference
      Overwhelmingly Chose Quest




                            Patients Growth People
Health Plan Contracting Approach
                                                                      »



»   Focused on Maintaining Mutually Beneficial
    Relationships

     Customize Solutions for Each Health Plan

     Offer Differentiated Service and Convenient
     Access for Their Members

      Price Competitively




                                                 Patients Growth People
Approach to Driving
                                        Profitable Growth
                                                                           »



» Building   a Sustainable Competitive Advantage
   Provide Differentiated Service at Competitive Prices
   Focus on High Growth Segments
       Cancer Diagnostics
       Cardiovascular Disease
       Infectious Disease
       Molecular Diagnostics
   Introduce Important & Unique Tests & Services
   Expand Geographic Scope
   Expand Diagnostic Scope – Near Patient Testing

  Increasing Loyalty with Patients, Physicians and Payers
                                                      Patients Growth People
AmeriPath Acquisition
                                                                             »



» Creates Leader in Cancer Diagnostics with 900 MDs and PhDs
      AmeriPath has National Scale with Significant Local Presence
           • Approximately 400 Pathologists and Clinical Scientists
           • Over 200 Hospital Contracts in 22 States
           • Approximately 40 Outpatient Facilities in 19 States
   Strengthens Leadership in Hospital and Esoteric Testing
   Strengthens Relationship with Physicians and Payers
   Accelerates Revenue and Earnings Growth




                                                        Patients Growth People
Financial Considerations
                                                                                 »



»   Enhances Long-term Shareholder Value and EPS Growth
      Leverage AmeriPath Brands and Pathologist Relationships
      Accelerate Overall Growth Through Cross-selling Clinical and AP
      Services
      Realize Economies of Scale on Esoteric Testing Business
    $2 Billion Total Transaction Value with Multiple of ~10x 2008 EBITDA
      Driven primarily by growth opportunities
      Cost synergies focused at Specialty Laboratories
            Rationalize capacity, logistics rationalization, improve
            purchasing capabilities, eliminate duplicate corporate costs
    Maintained Investment Grade Ratings

                                                            Patients Growth People
Near Patient Testing
                                                                               »



»   An Opportunity to Improve Patient Care and …
      Attractive benefits for hospitals and
      physician offices

      Enables more timely and effective
      decisions

      Expanding product menu

      Combine with central
      lab results to create
      complete patient
      testing record available to
      physicians and plans

    …to Reduce Medical Costs
                                                          Patients Growth People
Improving Revenue Mix to Higher
                                   Margin, Differentiated Services
                                                                                                         »
    Quest Diagnostics 2006A Revenue                     Pro Forma Quest Diagnostics Revenue

»                Other                                                  Other
                 8%                                                     7%
                             Gene-based and Esoteric                              Gene-based and Esoteric
Drugs of Abuse                                         Drugs of Abuse
                             16%                                                  17%
4%                                                     3%


                                 Anatomic Pathology                                     Anatomic Pathology
                                 10%                                                    17%
Routine                                                 Routine
62%                                                     56%


    Total Quest Revenue: $6.3 Billion
          AmeriPath 2006A Revenue                          Total Pro Forma Revenue: ~$7.0 Billion
                  Other
                  2%
                             Esoteric
                             20%




                                 Anatomic Pathology
                                 78%



 Total AmeriPath Revenue: $752 million
                                                                                    Patients Growth People
Building on Strength
                                                                      »



»   Industry Leader in a Vital and Growing Industry

      −Leadership in All Major Segments
    Unique Value Proposition

    A Proven Track Record of Integrating Acquisitions

    Proven Management Team

    Strong Cash Generator

    A History of Disciplined Growth

                                                 Patients Growth People
»



»




    Patients Growth People

Más contenido relacionado

La actualidad más candente

Joseph Dal Molin: Implementing VistA internationally: Myth-busting lessons fr...
Joseph Dal Molin: Implementing VistA internationally: Myth-busting lessons fr...Joseph Dal Molin: Implementing VistA internationally: Myth-busting lessons fr...
Joseph Dal Molin: Implementing VistA internationally: Myth-busting lessons fr...Nuffield Trust
 
A Look Under the Hood: 5 Critical Questions You Should be Asking about ACOs
A Look Under the Hood: 5 Critical Questions You Should be Asking about ACOsA Look Under the Hood: 5 Critical Questions You Should be Asking about ACOs
A Look Under the Hood: 5 Critical Questions You Should be Asking about ACOsSheri Litchford
 
The Dynamic State of Physician-Hospital Alignment: Using Collaboration and St...
The Dynamic State of Physician-Hospital Alignment: Using Collaboration and St...The Dynamic State of Physician-Hospital Alignment: Using Collaboration and St...
The Dynamic State of Physician-Hospital Alignment: Using Collaboration and St...Amy MacNulty
 
Real-World Evidence: A Better Life Journey for Pharmas, Payers and Patients
Real-World Evidence: A Better Life Journey for Pharmas, Payers and PatientsReal-World Evidence: A Better Life Journey for Pharmas, Payers and Patients
Real-World Evidence: A Better Life Journey for Pharmas, Payers and PatientsCognizant
 
Prepare For Health Reform With Revenue Cycle Management Insight From McKesson
Prepare For Health Reform With Revenue Cycle Management Insight From McKesson Prepare For Health Reform With Revenue Cycle Management Insight From McKesson
Prepare For Health Reform With Revenue Cycle Management Insight From McKesson revenuecyclem
 
Brian Griffin
Brian GriffinBrian Griffin
Brian GriffinInvestnet
 
RWE and Digital Health whitepaper (email)
RWE and Digital Health whitepaper (email)RWE and Digital Health whitepaper (email)
RWE and Digital Health whitepaper (email)Ulrich Neumann, FRSA
 
mHealth Israel_Cleveland Clinic_Innovaiton_Tom Sudow_June 2015
mHealth Israel_Cleveland Clinic_Innovaiton_Tom Sudow_June 2015mHealth Israel_Cleveland Clinic_Innovaiton_Tom Sudow_June 2015
mHealth Israel_Cleveland Clinic_Innovaiton_Tom Sudow_June 2015Levi Shapiro
 
mHealth Israel_Cleveland Clinic background_Tom Sudow, Director of Business De...
mHealth Israel_Cleveland Clinic background_Tom Sudow, Director of Business De...mHealth Israel_Cleveland Clinic background_Tom Sudow, Director of Business De...
mHealth Israel_Cleveland Clinic background_Tom Sudow, Director of Business De...Levi Shapiro
 
Wavefront guided custom cataract surgery
Wavefront guided custom cataract surgeryWavefront guided custom cataract surgery
Wavefront guided custom cataract surgerySM2 Strategic
 
Big data, RWE and AI in Clinical Trials made simple
Big data, RWE and AI in Clinical Trials made simpleBig data, RWE and AI in Clinical Trials made simple
Big data, RWE and AI in Clinical Trials made simpleHadas Jacoby
 
What We're Working On Now: Getting the "System" to be a Real System for Heart...
What We're Working On Now: Getting the "System" to be a Real System for Heart...What We're Working On Now: Getting the "System" to be a Real System for Heart...
What We're Working On Now: Getting the "System" to be a Real System for Heart...3GDR
 
iHT2 Health IT Summit in Phoenix 2013 – Terhilda Garrido, VP, HIT Tranformati...
iHT2 Health IT Summit in Phoenix 2013 – Terhilda Garrido, VP, HIT Tranformati...iHT2 Health IT Summit in Phoenix 2013 – Terhilda Garrido, VP, HIT Tranformati...
iHT2 Health IT Summit in Phoenix 2013 – Terhilda Garrido, VP, HIT Tranformati...Health IT Conference – iHT2
 
A Leading Patient Experience Survey Platform by MedStatix - White Labeled for...
A Leading Patient Experience Survey Platform by MedStatix - White Labeled for...A Leading Patient Experience Survey Platform by MedStatix - White Labeled for...
A Leading Patient Experience Survey Platform by MedStatix - White Labeled for...MedStatix, LLC
 

La actualidad más candente (15)

Joseph Dal Molin: Implementing VistA internationally: Myth-busting lessons fr...
Joseph Dal Molin: Implementing VistA internationally: Myth-busting lessons fr...Joseph Dal Molin: Implementing VistA internationally: Myth-busting lessons fr...
Joseph Dal Molin: Implementing VistA internationally: Myth-busting lessons fr...
 
A Look Under the Hood: 5 Critical Questions You Should be Asking about ACOs
A Look Under the Hood: 5 Critical Questions You Should be Asking about ACOsA Look Under the Hood: 5 Critical Questions You Should be Asking about ACOs
A Look Under the Hood: 5 Critical Questions You Should be Asking about ACOs
 
The Dynamic State of Physician-Hospital Alignment: Using Collaboration and St...
The Dynamic State of Physician-Hospital Alignment: Using Collaboration and St...The Dynamic State of Physician-Hospital Alignment: Using Collaboration and St...
The Dynamic State of Physician-Hospital Alignment: Using Collaboration and St...
 
Real-World Evidence: A Better Life Journey for Pharmas, Payers and Patients
Real-World Evidence: A Better Life Journey for Pharmas, Payers and PatientsReal-World Evidence: A Better Life Journey for Pharmas, Payers and Patients
Real-World Evidence: A Better Life Journey for Pharmas, Payers and Patients
 
Prepare For Health Reform With Revenue Cycle Management Insight From McKesson
Prepare For Health Reform With Revenue Cycle Management Insight From McKesson Prepare For Health Reform With Revenue Cycle Management Insight From McKesson
Prepare For Health Reform With Revenue Cycle Management Insight From McKesson
 
Brian Griffin
Brian GriffinBrian Griffin
Brian Griffin
 
RWE and Digital Health whitepaper (email)
RWE and Digital Health whitepaper (email)RWE and Digital Health whitepaper (email)
RWE and Digital Health whitepaper (email)
 
Decision time
Decision timeDecision time
Decision time
 
mHealth Israel_Cleveland Clinic_Innovaiton_Tom Sudow_June 2015
mHealth Israel_Cleveland Clinic_Innovaiton_Tom Sudow_June 2015mHealth Israel_Cleveland Clinic_Innovaiton_Tom Sudow_June 2015
mHealth Israel_Cleveland Clinic_Innovaiton_Tom Sudow_June 2015
 
mHealth Israel_Cleveland Clinic background_Tom Sudow, Director of Business De...
mHealth Israel_Cleveland Clinic background_Tom Sudow, Director of Business De...mHealth Israel_Cleveland Clinic background_Tom Sudow, Director of Business De...
mHealth Israel_Cleveland Clinic background_Tom Sudow, Director of Business De...
 
Wavefront guided custom cataract surgery
Wavefront guided custom cataract surgeryWavefront guided custom cataract surgery
Wavefront guided custom cataract surgery
 
Big data, RWE and AI in Clinical Trials made simple
Big data, RWE and AI in Clinical Trials made simpleBig data, RWE and AI in Clinical Trials made simple
Big data, RWE and AI in Clinical Trials made simple
 
What We're Working On Now: Getting the "System" to be a Real System for Heart...
What We're Working On Now: Getting the "System" to be a Real System for Heart...What We're Working On Now: Getting the "System" to be a Real System for Heart...
What We're Working On Now: Getting the "System" to be a Real System for Heart...
 
iHT2 Health IT Summit in Phoenix 2013 – Terhilda Garrido, VP, HIT Tranformati...
iHT2 Health IT Summit in Phoenix 2013 – Terhilda Garrido, VP, HIT Tranformati...iHT2 Health IT Summit in Phoenix 2013 – Terhilda Garrido, VP, HIT Tranformati...
iHT2 Health IT Summit in Phoenix 2013 – Terhilda Garrido, VP, HIT Tranformati...
 
A Leading Patient Experience Survey Platform by MedStatix - White Labeled for...
A Leading Patient Experience Survey Platform by MedStatix - White Labeled for...A Leading Patient Experience Survey Platform by MedStatix - White Labeled for...
A Leading Patient Experience Survey Platform by MedStatix - White Labeled for...
 

Destacado

SP, Workforce Singapore and Agilent Technologies Lean Enterprise Development ...
SP, Workforce Singapore and Agilent Technologies Lean Enterprise Development ...SP, Workforce Singapore and Agilent Technologies Lean Enterprise Development ...
SP, Workforce Singapore and Agilent Technologies Lean Enterprise Development ...Serene Leong
 
agilent_2000_ar
agilent_2000_aragilent_2000_ar
agilent_2000_arfinance38
 
Managing Services Spend ...
Managing Services Spend ...Managing Services Spend ...
Managing Services Spend ...Peter Woon
 
Agilent Technologies Corporate Overview
Agilent Technologies Corporate OverviewAgilent Technologies Corporate Overview
Agilent Technologies Corporate Overviewrajsodhi
 
Thermo Fisher Scientific Kanban Project Poster_AYA
Thermo Fisher Scientific Kanban Project Poster_AYAThermo Fisher Scientific Kanban Project Poster_AYA
Thermo Fisher Scientific Kanban Project Poster_AYAAna (Anya) Soloviov
 
Managing the Cold Chain to Minimize Pre-Analytical Variability
Managing the Cold Chain to Minimize Pre-Analytical VariabilityManaging the Cold Chain to Minimize Pre-Analytical Variability
Managing the Cold Chain to Minimize Pre-Analytical VariabilityThermo Fisher Scientific
 
Cell Biology Antibodies
Cell Biology AntibodiesCell Biology Antibodies
Cell Biology AntibodiesElabscience
 
Thermofisher scientific ltd- organisational behaviour
Thermofisher scientific ltd- organisational behaviourThermofisher scientific ltd- organisational behaviour
Thermofisher scientific ltd- organisational behaviourDhruv Chakravarty
 
thermo fisher ED886123-7163-46F5-8387-5F57485F786B_FINAL09SHOW_III
thermo fisher ED886123-7163-46F5-8387-5F57485F786B_FINAL09SHOW_IIIthermo fisher ED886123-7163-46F5-8387-5F57485F786B_FINAL09SHOW_III
thermo fisher ED886123-7163-46F5-8387-5F57485F786B_FINAL09SHOW_IIIfinance40
 
GovTech Market Snapshot
GovTech Market SnapshotGovTech Market Snapshot
GovTech Market SnapshotDustin Haisler
 

Destacado (18)

SP, Workforce Singapore and Agilent Technologies Lean Enterprise Development ...
SP, Workforce Singapore and Agilent Technologies Lean Enterprise Development ...SP, Workforce Singapore and Agilent Technologies Lean Enterprise Development ...
SP, Workforce Singapore and Agilent Technologies Lean Enterprise Development ...
 
usg AR_2000
usg AR_2000usg AR_2000
usg AR_2000
 
agilent_2000_ar
agilent_2000_aragilent_2000_ar
agilent_2000_ar
 
2016 06 08 neo company overview presentation
2016 06 08   neo company overview presentation2016 06 08   neo company overview presentation
2016 06 08 neo company overview presentation
 
Emerging Labs in Healthcare
Emerging Labs in HealthcareEmerging Labs in Healthcare
Emerging Labs in Healthcare
 
NGNM Company Overview Presentation
NGNM Company Overview PresentationNGNM Company Overview Presentation
NGNM Company Overview Presentation
 
Salmonella Fact Sheet
Salmonella Fact SheetSalmonella Fact Sheet
Salmonella Fact Sheet
 
Managing Services Spend ...
Managing Services Spend ...Managing Services Spend ...
Managing Services Spend ...
 
Vibrio Infographic
Vibrio InfographicVibrio Infographic
Vibrio Infographic
 
Agilent Technologies Corporate Overview
Agilent Technologies Corporate OverviewAgilent Technologies Corporate Overview
Agilent Technologies Corporate Overview
 
Mycoplasma Infographic
Mycoplasma Infographic Mycoplasma Infographic
Mycoplasma Infographic
 
We've moved!
We've moved!We've moved!
We've moved!
 
Thermo Fisher Scientific Kanban Project Poster_AYA
Thermo Fisher Scientific Kanban Project Poster_AYAThermo Fisher Scientific Kanban Project Poster_AYA
Thermo Fisher Scientific Kanban Project Poster_AYA
 
Managing the Cold Chain to Minimize Pre-Analytical Variability
Managing the Cold Chain to Minimize Pre-Analytical VariabilityManaging the Cold Chain to Minimize Pre-Analytical Variability
Managing the Cold Chain to Minimize Pre-Analytical Variability
 
Cell Biology Antibodies
Cell Biology AntibodiesCell Biology Antibodies
Cell Biology Antibodies
 
Thermofisher scientific ltd- organisational behaviour
Thermofisher scientific ltd- organisational behaviourThermofisher scientific ltd- organisational behaviour
Thermofisher scientific ltd- organisational behaviour
 
thermo fisher ED886123-7163-46F5-8387-5F57485F786B_FINAL09SHOW_III
thermo fisher ED886123-7163-46F5-8387-5F57485F786B_FINAL09SHOW_IIIthermo fisher ED886123-7163-46F5-8387-5F57485F786B_FINAL09SHOW_III
thermo fisher ED886123-7163-46F5-8387-5F57485F786B_FINAL09SHOW_III
 
GovTech Market Snapshot
GovTech Market SnapshotGovTech Market Snapshot
GovTech Market Snapshot
 

Similar a quest diagnostics 6_25Jefferies6_26_07

quest diagnostics 9_21UBSConf9_24_07Update9_21_07
quest diagnostics 9_21UBSConf9_24_07Update9_21_07quest diagnostics 9_21UBSConf9_24_07Update9_21_07
quest diagnostics 9_21UBSConf9_24_07Update9_21_07finance34
 
quest diagnostics quest diagnostics 111208_CSHCC
quest diagnostics quest diagnostics 111208_CSHCCquest diagnostics quest diagnostics 111208_CSHCC
quest diagnostics quest diagnostics 111208_CSHCCfinance34
 
quest diagnostics UBS9_24_08
quest diagnostics UBS9_24_08quest diagnostics UBS9_24_08
quest diagnostics UBS9_24_08finance34
 
quest diagnostics 8171932C-60AA-469C-929A-995B7737DF39_BarclaysPresentation3....
quest diagnostics 8171932C-60AA-469C-929A-995B7737DF39_BarclaysPresentation3....quest diagnostics 8171932C-60AA-469C-929A-995B7737DF39_BarclaysPresentation3....
quest diagnostics 8171932C-60AA-469C-929A-995B7737DF39_BarclaysPresentation3....finance34
 
quest diagnostics Jefferies_Conf_6_24_08
quest diagnostics Jefferies_Conf_6_24_08quest diagnostics Jefferies_Conf_6_24_08
quest diagnostics Jefferies_Conf_6_24_08finance34
 
World Health Care Congress - 21st Century Health System0090412
World Health Care Congress - 21st Century Health System0090412World Health Care Congress - 21st Century Health System0090412
World Health Care Congress - 21st Century Health System0090412scottshreeve
 
quest diagnostics 3_18_08Cowen
quest diagnostics 3_18_08Cowenquest diagnostics 3_18_08Cowen
quest diagnostics 3_18_08Cowenfinance34
 
Pcori challenge hd
Pcori challenge hdPcori challenge hd
Pcori challenge hdhbocian14
 
World Health Congress 2009 Europe Market Insight
World Health Congress 2009 Europe Market InsightWorld Health Congress 2009 Europe Market Insight
World Health Congress 2009 Europe Market Insightrongyi
 
quest diagnostics 3_18_08Cowen
quest diagnostics 3_18_08Cowenquest diagnostics 3_18_08Cowen
quest diagnostics 3_18_08Cowenfinance34
 
Right Care @ the NaPC Conference
Right Care @ the NaPC ConferenceRight Care @ the NaPC Conference
Right Care @ the NaPC Conferencerightcare
 
Improving Health Care Quality Through Integrated Teams
Improving Health Care Quality Through Integrated TeamsImproving Health Care Quality Through Integrated Teams
Improving Health Care Quality Through Integrated TeamsPlan de Calidad para el SNS
 
Cellgen - Companion Diagnostic Platform
Cellgen - Companion Diagnostic PlatformCellgen - Companion Diagnostic Platform
Cellgen - Companion Diagnostic PlatformLavance L. Northington
 
Findhealth
FindhealthFindhealth
FindhealthAnna Jo
 
What eHealth strategies work and do not work, and what should be implemented ...
What eHealth strategies work and do not work, and what should be implemented ...What eHealth strategies work and do not work, and what should be implemented ...
What eHealth strategies work and do not work, and what should be implemented ...Plan de Calidad para el SNS
 

Similar a quest diagnostics 6_25Jefferies6_26_07 (20)

quest diagnostics 9_21UBSConf9_24_07Update9_21_07
quest diagnostics 9_21UBSConf9_24_07Update9_21_07quest diagnostics 9_21UBSConf9_24_07Update9_21_07
quest diagnostics 9_21UBSConf9_24_07Update9_21_07
 
quest diagnostics quest diagnostics 111208_CSHCC
quest diagnostics quest diagnostics 111208_CSHCCquest diagnostics quest diagnostics 111208_CSHCC
quest diagnostics quest diagnostics 111208_CSHCC
 
quest diagnostics UBS9_24_08
quest diagnostics UBS9_24_08quest diagnostics UBS9_24_08
quest diagnostics UBS9_24_08
 
quest diagnostics 8171932C-60AA-469C-929A-995B7737DF39_BarclaysPresentation3....
quest diagnostics 8171932C-60AA-469C-929A-995B7737DF39_BarclaysPresentation3....quest diagnostics 8171932C-60AA-469C-929A-995B7737DF39_BarclaysPresentation3....
quest diagnostics 8171932C-60AA-469C-929A-995B7737DF39_BarclaysPresentation3....
 
quest diagnostics Jefferies_Conf_6_24_08
quest diagnostics Jefferies_Conf_6_24_08quest diagnostics Jefferies_Conf_6_24_08
quest diagnostics Jefferies_Conf_6_24_08
 
World Health Care Congress - 21st Century Health System0090412
World Health Care Congress - 21st Century Health System0090412World Health Care Congress - 21st Century Health System0090412
World Health Care Congress - 21st Century Health System0090412
 
quest diagnostics 3_18_08Cowen
quest diagnostics 3_18_08Cowenquest diagnostics 3_18_08Cowen
quest diagnostics 3_18_08Cowen
 
Pcori challenge hd
Pcori challenge hdPcori challenge hd
Pcori challenge hd
 
World Health Congress 2009 Europe Market Insight
World Health Congress 2009 Europe Market InsightWorld Health Congress 2009 Europe Market Insight
World Health Congress 2009 Europe Market Insight
 
e-MDs Summary Overview
e-MDs Summary Overviewe-MDs Summary Overview
e-MDs Summary Overview
 
quest diagnostics 3_18_08Cowen
quest diagnostics 3_18_08Cowenquest diagnostics 3_18_08Cowen
quest diagnostics 3_18_08Cowen
 
Right Care @ the NaPC Conference
Right Care @ the NaPC ConferenceRight Care @ the NaPC Conference
Right Care @ the NaPC Conference
 
Improving Health Care Quality Through Integrated Teams
Improving Health Care Quality Through Integrated TeamsImproving Health Care Quality Through Integrated Teams
Improving Health Care Quality Through Integrated Teams
 
Cellgen - Companion Diagnostic Platform
Cellgen - Companion Diagnostic PlatformCellgen - Companion Diagnostic Platform
Cellgen - Companion Diagnostic Platform
 
Findhealth
FindhealthFindhealth
Findhealth
 
Breton&Lagalia
Breton&LagaliaBreton&Lagalia
Breton&Lagalia
 
What eHealth strategies work and do not work, and what should be implemented ...
What eHealth strategies work and do not work, and what should be implemented ...What eHealth strategies work and do not work, and what should be implemented ...
What eHealth strategies work and do not work, and what should be implemented ...
 
04 cgix
04 cgix04 cgix
04 cgix
 
CGIX Investor presentation
CGIX Investor presentationCGIX Investor presentation
CGIX Investor presentation
 
Cgix investor presentation Oct 2014
Cgix investor presentation Oct 2014Cgix investor presentation Oct 2014
Cgix investor presentation Oct 2014
 

Más de finance34

charter communications 1Qslides_FINAL
charter communications 1Qslides_FINALcharter communications 1Qslides_FINAL
charter communications 1Qslides_FINALfinance34
 
charter communications 1Qslides_FINAL
charter communications 1Qslides_FINALcharter communications 1Qslides_FINAL
charter communications 1Qslides_FINALfinance34
 
charter communications 2Q07_Slides
charter communications 2Q07_Slidescharter communications 2Q07_Slides
charter communications 2Q07_Slidesfinance34
 
charter communications 2Q07_Slides
charter communications 2Q07_Slidescharter communications 2Q07_Slides
charter communications 2Q07_Slidesfinance34
 
charter communications 4Q2007_Earnings_Presentation_vFINAL
charter communications 4Q2007_Earnings_Presentation_vFINALcharter communications 4Q2007_Earnings_Presentation_vFINAL
charter communications 4Q2007_Earnings_Presentation_vFINALfinance34
 
charter communications 4Q2007_Earnings_Presentation_vFINAL
charter communications 4Q2007_Earnings_Presentation_vFINALcharter communications 4Q2007_Earnings_Presentation_vFINAL
charter communications 4Q2007_Earnings_Presentation_vFINALfinance34
 
charter communications 1Q_2008_Earnings_Presentation
charter communications 1Q_2008_Earnings_Presentationcharter communications 1Q_2008_Earnings_Presentation
charter communications 1Q_2008_Earnings_Presentationfinance34
 
charter communications 1Q_2008_Earnings_Presentation
charter communications 1Q_2008_Earnings_Presentationcharter communications 1Q_2008_Earnings_Presentation
charter communications 1Q_2008_Earnings_Presentationfinance34
 
charter communications 2Q_2008_Earnings_Presentation_FINAL
charter communications 2Q_2008_Earnings_Presentation_FINALcharter communications 2Q_2008_Earnings_Presentation_FINAL
charter communications 2Q_2008_Earnings_Presentation_FINALfinance34
 
charter communications 2Q_2008_Earnings_Presentation_FINAL
charter communications 2Q_2008_Earnings_Presentation_FINALcharter communications 2Q_2008_Earnings_Presentation_FINAL
charter communications 2Q_2008_Earnings_Presentation_FINALfinance34
 
charter communications 3Q_2008_Earnings_Presentation_vFINAL
charter communications 3Q_2008_Earnings_Presentation_vFINALcharter communications 3Q_2008_Earnings_Presentation_vFINAL
charter communications 3Q_2008_Earnings_Presentation_vFINALfinance34
 
charter communications 3Q_2008_Earnings_Presentation_vFINAL
charter communications 3Q_2008_Earnings_Presentation_vFINALcharter communications 3Q_2008_Earnings_Presentation_vFINAL
charter communications 3Q_2008_Earnings_Presentation_vFINALfinance34
 
charter communications proxy00
charter communications proxy00charter communications proxy00
charter communications proxy00finance34
 
charter communications proxy00
charter communications proxy00charter communications proxy00
charter communications proxy00finance34
 
CHRT_000502__154_120
CHRT_000502__154_120CHRT_000502__154_120
CHRT_000502__154_120finance34
 
CHRT_000502__154_120
CHRT_000502__154_120CHRT_000502__154_120
CHRT_000502__154_120finance34
 
charter communications ar_00
charter communications ar_00charter communications ar_00
charter communications ar_00finance34
 
charter communications ar_00
charter communications ar_00charter communications ar_00
charter communications ar_00finance34
 

Más de finance34 (20)

charter communications 1Qslides_FINAL
charter communications 1Qslides_FINALcharter communications 1Qslides_FINAL
charter communications 1Qslides_FINAL
 
charter communications 1Qslides_FINAL
charter communications 1Qslides_FINALcharter communications 1Qslides_FINAL
charter communications 1Qslides_FINAL
 
charter communications 2Q07_Slides
charter communications 2Q07_Slidescharter communications 2Q07_Slides
charter communications 2Q07_Slides
 
charter communications 2Q07_Slides
charter communications 2Q07_Slidescharter communications 2Q07_Slides
charter communications 2Q07_Slides
 
charter communications 4Q2007_Earnings_Presentation_vFINAL
charter communications 4Q2007_Earnings_Presentation_vFINALcharter communications 4Q2007_Earnings_Presentation_vFINAL
charter communications 4Q2007_Earnings_Presentation_vFINAL
 
charter communications 4Q2007_Earnings_Presentation_vFINAL
charter communications 4Q2007_Earnings_Presentation_vFINALcharter communications 4Q2007_Earnings_Presentation_vFINAL
charter communications 4Q2007_Earnings_Presentation_vFINAL
 
charter communications 1Q_2008_Earnings_Presentation
charter communications 1Q_2008_Earnings_Presentationcharter communications 1Q_2008_Earnings_Presentation
charter communications 1Q_2008_Earnings_Presentation
 
charter communications 1Q_2008_Earnings_Presentation
charter communications 1Q_2008_Earnings_Presentationcharter communications 1Q_2008_Earnings_Presentation
charter communications 1Q_2008_Earnings_Presentation
 
charter communications 2Q_2008_Earnings_Presentation_FINAL
charter communications 2Q_2008_Earnings_Presentation_FINALcharter communications 2Q_2008_Earnings_Presentation_FINAL
charter communications 2Q_2008_Earnings_Presentation_FINAL
 
charter communications 2Q_2008_Earnings_Presentation_FINAL
charter communications 2Q_2008_Earnings_Presentation_FINALcharter communications 2Q_2008_Earnings_Presentation_FINAL
charter communications 2Q_2008_Earnings_Presentation_FINAL
 
charter communications 3Q_2008_Earnings_Presentation_vFINAL
charter communications 3Q_2008_Earnings_Presentation_vFINALcharter communications 3Q_2008_Earnings_Presentation_vFINAL
charter communications 3Q_2008_Earnings_Presentation_vFINAL
 
charter communications 3Q_2008_Earnings_Presentation_vFINAL
charter communications 3Q_2008_Earnings_Presentation_vFINALcharter communications 3Q_2008_Earnings_Presentation_vFINAL
charter communications 3Q_2008_Earnings_Presentation_vFINAL
 
charter communications proxy00
charter communications proxy00charter communications proxy00
charter communications proxy00
 
charter communications proxy00
charter communications proxy00charter communications proxy00
charter communications proxy00
 
CHRT_000502__154_120
CHRT_000502__154_120CHRT_000502__154_120
CHRT_000502__154_120
 
CHRT_000502__154_120
CHRT_000502__154_120CHRT_000502__154_120
CHRT_000502__154_120
 
chtr_010502
chtr_010502chtr_010502
chtr_010502
 
chtr_010502
chtr_010502chtr_010502
chtr_010502
 
charter communications ar_00
charter communications ar_00charter communications ar_00
charter communications ar_00
 
charter communications ar_00
charter communications ar_00charter communications ar_00
charter communications ar_00
 

Último

Hungarys economy made by Robert Miklos
Hungarys economy   made by Robert MiklosHungarys economy   made by Robert Miklos
Hungarys economy made by Robert Miklosbeduinpower135
 
Monthly Market Risk Update: March 2024 [SlideShare]
Monthly Market Risk Update: March 2024 [SlideShare]Monthly Market Risk Update: March 2024 [SlideShare]
Monthly Market Risk Update: March 2024 [SlideShare]Commonwealth
 
Stock Market Brief Deck for March 19 2024.pdf
Stock Market Brief Deck for March 19 2024.pdfStock Market Brief Deck for March 19 2024.pdf
Stock Market Brief Deck for March 19 2024.pdfMichael Silva
 
20240315 _E-Invoicing Digiteal. .pptx
20240315 _E-Invoicing Digiteal.    .pptx20240315 _E-Invoicing Digiteal.    .pptx
20240315 _E-Invoicing Digiteal. .pptxFinTech Belgium
 
CLUB DEAL - DECK INVESTOR
CLUB DEAL - DECK INVESTORCLUB DEAL - DECK INVESTOR
CLUB DEAL - DECK INVESTORhnaour
 
20240314 Calibre March 2024 Investor Presentation (FINAL).pdf
20240314 Calibre March 2024 Investor Presentation (FINAL).pdf20240314 Calibre March 2024 Investor Presentation (FINAL).pdf
20240314 Calibre March 2024 Investor Presentation (FINAL).pdfAdnet Communications
 
ENT ospe 1 .pdf .....good and easy for medical
ENT ospe 1 .pdf .....good and easy for medicalENT ospe 1 .pdf .....good and easy for medical
ENT ospe 1 .pdf .....good and easy for medicalabaidurrehman0546
 
RWA Report 2024: Rise of Real-World Assets in Crypto | CoinGecko
RWA Report 2024: Rise of Real-World Assets in Crypto | CoinGeckoRWA Report 2024: Rise of Real-World Assets in Crypto | CoinGecko
RWA Report 2024: Rise of Real-World Assets in Crypto | CoinGeckoCoinGecko
 
ACCOUNTING FOR BUSINESS.II BRANCH ACCOUNTS NOTES
ACCOUNTING FOR BUSINESS.II BRANCH ACCOUNTS NOTESACCOUNTING FOR BUSINESS.II BRANCH ACCOUNTS NOTES
ACCOUNTING FOR BUSINESS.II BRANCH ACCOUNTS NOTESKumarJayaraman3
 
Lundin Gold March 2024 Corporate Presentation - PDAC v1.pdf
Lundin Gold March 2024 Corporate Presentation - PDAC v1.pdfLundin Gold March 2024 Corporate Presentation - PDAC v1.pdf
Lundin Gold March 2024 Corporate Presentation - PDAC v1.pdfAdnet Communications
 
2024.03 Strategic Resources Presentation
2024.03 Strategic Resources Presentation2024.03 Strategic Resources Presentation
2024.03 Strategic Resources PresentationAdnet Communications
 
Shrambal_Distributors_Newsletter_Mar_2024.pdf
Shrambal_Distributors_Newsletter_Mar_2024.pdfShrambal_Distributors_Newsletter_Mar_2024.pdf
Shrambal_Distributors_Newsletter_Mar_2024.pdfvikashdidwania1
 
Contracts with Interdependent Preferences
Contracts with Interdependent PreferencesContracts with Interdependent Preferences
Contracts with Interdependent PreferencesGRAPE
 
Sarlat Advisory - Corporate Brochure - 2024
Sarlat Advisory - Corporate Brochure - 2024Sarlat Advisory - Corporate Brochure - 2024
Sarlat Advisory - Corporate Brochure - 2024Guillaume Ⓥ Sarlat
 
CLUB DEAL -DECK INVESTOR
CLUB DEAL -DECK INVESTORCLUB DEAL -DECK INVESTOR
CLUB DEAL -DECK INVESTORhnaour
 
Introduction to Entrepreneurship and Characteristics of an Entrepreneur
Introduction to Entrepreneurship and Characteristics of an EntrepreneurIntroduction to Entrepreneurship and Characteristics of an Entrepreneur
Introduction to Entrepreneurship and Characteristics of an Entrepreneurabcisahunter
 
Slideshare - ONS Economic Forum Slidepack - 18 March 2024.pptx
Slideshare - ONS Economic Forum Slidepack - 18 March 2024.pptxSlideshare - ONS Economic Forum Slidepack - 18 March 2024.pptx
Slideshare - ONS Economic Forum Slidepack - 18 March 2024.pptxOffice for National Statistics
 
CSR01P4 The foundations of CSR Part 4 Economic
CSR01P4 The foundations of CSR Part 4 EconomicCSR01P4 The foundations of CSR Part 4 Economic
CSR01P4 The foundations of CSR Part 4 EconomicMatthieu Bruckert
 

Último (20)

New Monthly Enterprises Survey. Issue 21. (01.2024) Ukrainian Business in War...
New Monthly Enterprises Survey. Issue 21. (01.2024) Ukrainian Business in War...New Monthly Enterprises Survey. Issue 21. (01.2024) Ukrainian Business in War...
New Monthly Enterprises Survey. Issue 21. (01.2024) Ukrainian Business in War...
 
Hungarys economy made by Robert Miklos
Hungarys economy   made by Robert MiklosHungarys economy   made by Robert Miklos
Hungarys economy made by Robert Miklos
 
Monthly Market Risk Update: March 2024 [SlideShare]
Monthly Market Risk Update: March 2024 [SlideShare]Monthly Market Risk Update: March 2024 [SlideShare]
Monthly Market Risk Update: March 2024 [SlideShare]
 
Stock Market Brief Deck for March 19 2024.pdf
Stock Market Brief Deck for March 19 2024.pdfStock Market Brief Deck for March 19 2024.pdf
Stock Market Brief Deck for March 19 2024.pdf
 
20240315 _E-Invoicing Digiteal. .pptx
20240315 _E-Invoicing Digiteal.    .pptx20240315 _E-Invoicing Digiteal.    .pptx
20240315 _E-Invoicing Digiteal. .pptx
 
CLUB DEAL - DECK INVESTOR
CLUB DEAL - DECK INVESTORCLUB DEAL - DECK INVESTOR
CLUB DEAL - DECK INVESTOR
 
20240314 Calibre March 2024 Investor Presentation (FINAL).pdf
20240314 Calibre March 2024 Investor Presentation (FINAL).pdf20240314 Calibre March 2024 Investor Presentation (FINAL).pdf
20240314 Calibre March 2024 Investor Presentation (FINAL).pdf
 
ENT ospe 1 .pdf .....good and easy for medical
ENT ospe 1 .pdf .....good and easy for medicalENT ospe 1 .pdf .....good and easy for medical
ENT ospe 1 .pdf .....good and easy for medical
 
RWA Report 2024: Rise of Real-World Assets in Crypto | CoinGecko
RWA Report 2024: Rise of Real-World Assets in Crypto | CoinGeckoRWA Report 2024: Rise of Real-World Assets in Crypto | CoinGecko
RWA Report 2024: Rise of Real-World Assets in Crypto | CoinGecko
 
ACCOUNTING FOR BUSINESS.II BRANCH ACCOUNTS NOTES
ACCOUNTING FOR BUSINESS.II BRANCH ACCOUNTS NOTESACCOUNTING FOR BUSINESS.II BRANCH ACCOUNTS NOTES
ACCOUNTING FOR BUSINESS.II BRANCH ACCOUNTS NOTES
 
Lundin Gold March 2024 Corporate Presentation - PDAC v1.pdf
Lundin Gold March 2024 Corporate Presentation - PDAC v1.pdfLundin Gold March 2024 Corporate Presentation - PDAC v1.pdf
Lundin Gold March 2024 Corporate Presentation - PDAC v1.pdf
 
2024.03 Strategic Resources Presentation
2024.03 Strategic Resources Presentation2024.03 Strategic Resources Presentation
2024.03 Strategic Resources Presentation
 
Shrambal_Distributors_Newsletter_Mar_2024.pdf
Shrambal_Distributors_Newsletter_Mar_2024.pdfShrambal_Distributors_Newsletter_Mar_2024.pdf
Shrambal_Distributors_Newsletter_Mar_2024.pdf
 
Effects & Policies Of Bank Consolidation
Effects & Policies Of Bank ConsolidationEffects & Policies Of Bank Consolidation
Effects & Policies Of Bank Consolidation
 
Contracts with Interdependent Preferences
Contracts with Interdependent PreferencesContracts with Interdependent Preferences
Contracts with Interdependent Preferences
 
Sarlat Advisory - Corporate Brochure - 2024
Sarlat Advisory - Corporate Brochure - 2024Sarlat Advisory - Corporate Brochure - 2024
Sarlat Advisory - Corporate Brochure - 2024
 
CLUB DEAL -DECK INVESTOR
CLUB DEAL -DECK INVESTORCLUB DEAL -DECK INVESTOR
CLUB DEAL -DECK INVESTOR
 
Introduction to Entrepreneurship and Characteristics of an Entrepreneur
Introduction to Entrepreneurship and Characteristics of an EntrepreneurIntroduction to Entrepreneurship and Characteristics of an Entrepreneur
Introduction to Entrepreneurship and Characteristics of an Entrepreneur
 
Slideshare - ONS Economic Forum Slidepack - 18 March 2024.pptx
Slideshare - ONS Economic Forum Slidepack - 18 March 2024.pptxSlideshare - ONS Economic Forum Slidepack - 18 March 2024.pptx
Slideshare - ONS Economic Forum Slidepack - 18 March 2024.pptx
 
CSR01P4 The foundations of CSR Part 4 Economic
CSR01P4 The foundations of CSR Part 4 EconomicCSR01P4 The foundations of CSR Part 4 Economic
CSR01P4 The foundations of CSR Part 4 Economic
 

quest diagnostics 6_25Jefferies6_26_07

  • 1. Jefferies Healthcare Conference June 26, 2007
  • 2. Safe Harbor Disclaimer » » The statements in this presentation which are not historical facts or information are forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the outcome to be materially different. Certain of these risks and uncertainties are described in the Quest Diagnostics Incorporated SEC filings, including our latest Form 10-K. Additional risks may arise from unanticipated events. A copy of this presentation is available on our website at www.questdiagnostics.com Patients Growth People
  • 3. Who is Quest Diagnostics? » »Leader in Providing Healthcare Insights and Solutions Comprehensive Diagnostic Testing Routine ——» Esoteric • Diagnose • Monitor • Predict • Prevent Advanced Information Technology Solutions Improve Care and Efficiency Facilitate Introduction of New Therapeutics Clinical Trials Testing Touching the Lives of Patients >150 Million Times in 2006 Patients Growth People
  • 4. Quest Diagnostics: The Leader » » DiagnosticBTesting US Market: ~$45 Source: Washington G-2 Reports and company estimates Quest Diagnostics data is proforma for AmeriPath acquisition Patients Growth People
  • 5. A Leader Across All Product Lines » » $ in millions Based on 2006 Actual Results, proforma for AmeriPath acquisition Patients Growth People
  • 6. Favorable Industry Trends » » Essential Healthcare Service Growing and Aging Population Innovations in Science & Medicine Personal Interest in Health Convergence of Technologies • Genetic Predisposition • Diagnostic Testing • Diagnostic Imaging • Information Technology Influences >70% of Healthcare Decisions Patients Growth People
  • 7. Why Quest Diagnostics? » » Unique Value Proposition Superior Patient Experience Six Sigma Quality Unparalleled Access and Distribution Innovative Science & Medicine Advanced Information Technology Sustainable Advantage Patients Growth People
  • 8. Patient Service Centers and Laboratory Network » » PSCs IOPs RRLs ∃ Main Labs ∃ ~2,300 Laboratories and Patient Service Centers Serving Half of US Physicians Patients Growth People
  • 9. Electronic Connectivity: Care360 Network » » >100,000 Physician Users and Growing by >1,000 Physicians Each Month Patients Growth People
  • 10. Preferred by Physicians » » Recent Nationwide Survey Completed by National Analysts Worldwide Asked If Physicians Had a Preference Between 2 Largest Labs: Majority Had a Preference Overwhelmingly Chose Quest Patients Growth People
  • 11. Health Plan Contracting Approach » » Focused on Maintaining Mutually Beneficial Relationships Customize Solutions for Each Health Plan Offer Differentiated Service and Convenient Access for Their Members Price Competitively Patients Growth People
  • 12. Approach to Driving Profitable Growth » » Building a Sustainable Competitive Advantage Provide Differentiated Service at Competitive Prices Focus on High Growth Segments Cancer Diagnostics Cardiovascular Disease Infectious Disease Molecular Diagnostics Introduce Important & Unique Tests & Services Expand Geographic Scope Expand Diagnostic Scope – Near Patient Testing Increasing Loyalty with Patients, Physicians and Payers Patients Growth People
  • 13. AmeriPath Acquisition » » Creates Leader in Cancer Diagnostics with 900 MDs and PhDs AmeriPath has National Scale with Significant Local Presence • Approximately 400 Pathologists and Clinical Scientists • Over 200 Hospital Contracts in 22 States • Approximately 40 Outpatient Facilities in 19 States Strengthens Leadership in Hospital and Esoteric Testing Strengthens Relationship with Physicians and Payers Accelerates Revenue and Earnings Growth Patients Growth People
  • 14. Financial Considerations » » Enhances Long-term Shareholder Value and EPS Growth Leverage AmeriPath Brands and Pathologist Relationships Accelerate Overall Growth Through Cross-selling Clinical and AP Services Realize Economies of Scale on Esoteric Testing Business $2 Billion Total Transaction Value with Multiple of ~10x 2008 EBITDA Driven primarily by growth opportunities Cost synergies focused at Specialty Laboratories Rationalize capacity, logistics rationalization, improve purchasing capabilities, eliminate duplicate corporate costs Maintained Investment Grade Ratings Patients Growth People
  • 15. Near Patient Testing » » An Opportunity to Improve Patient Care and … Attractive benefits for hospitals and physician offices Enables more timely and effective decisions Expanding product menu Combine with central lab results to create complete patient testing record available to physicians and plans …to Reduce Medical Costs Patients Growth People
  • 16. Improving Revenue Mix to Higher Margin, Differentiated Services » Quest Diagnostics 2006A Revenue Pro Forma Quest Diagnostics Revenue » Other Other 8% 7% Gene-based and Esoteric Gene-based and Esoteric Drugs of Abuse Drugs of Abuse 16% 17% 4% 3% Anatomic Pathology Anatomic Pathology 10% 17% Routine Routine 62% 56% Total Quest Revenue: $6.3 Billion AmeriPath 2006A Revenue Total Pro Forma Revenue: ~$7.0 Billion Other 2% Esoteric 20% Anatomic Pathology 78% Total AmeriPath Revenue: $752 million Patients Growth People
  • 17. Building on Strength » » Industry Leader in a Vital and Growing Industry −Leadership in All Major Segments Unique Value Proposition A Proven Track Record of Integrating Acquisitions Proven Management Team Strong Cash Generator A History of Disciplined Growth Patients Growth People
  • 18. » » Patients Growth People